Investigational Site Number :7240008

Madrid 28046

2 studies enrolling now · 6 studies all time

What they study most

Alopecia Areata, Asthma, Atopic Dermatitis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Heart Failure, Immune Thrombocytopenia, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment — Recruiting now
• Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata — Stopped early
• SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" — Completed
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) — Stopped early